No indication of increased infection rates using low‐dose alemtuzumab instead of anti‐thymocyte globulin as graft‐versus‐host disease prophylaxis before allogeneic stem cell transplantation

Publisher: John Wiley & Sons Inc

E-ISSN: 1399-3062|20|1|tid.12822-tid.12822

ISSN: 1398-2273

Source: TRANSPLANT INFECTIOUS DISEASE (ELECTRONIC), Vol.20, Iss.1, 2018-02, pp. : n/a-n/a

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content